Publications scientifiques
Retrouvez les travaux consacrés aux programmes d’AB Science.
Les publications sont regroupées par programme et donnent accès aux articles ou à leur référence scientifique en ligne.
Sclérose en plaques — 4 publications disponibles
Masitinib is an oral, brain penetrant inhibitor of microglial and mast cell activity with neuroprotective potential in progressive forms of multiple sclerosis↗Tyrosine kinase inhibitor, masitinib, limits neuronal damage, as measured by serum neurofilament light chain concentration in a model of neuroimmune-driven neurodegenerative disease↗Efficacy and safety of masitinib in progressive forms of multiple sclerosis: a randomized, phase 3, clinical trial↗Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study↗
Sclérose latérale amyotrophique — 13 publications disponibles
Evaluation of long-term amyotrophic lateral sclerosis survivors treated with masitinib in study AB10015↗Efficacy and safety of masitinib in amyotrophic lateral sclerosis patients prior to loss of functionality: a subgroup analysis optimizing the benefit-risk profile of masitinib↗Categorization of the amyotrophic lateral sclerosis population via the clinical determinant of post-onset ΔFS for study design and medical practice↗Long-term survival analysis of masitinib in amyotrophic lateral sclerosis↗The pathogenic role of c-Kit+ mast cells in the spinal motor neuron-vascular niche in ALS↗Muscle fiber-type specific terminal Schwann cell pathology leads to sprouting deficits following partial denervation in SOD1G93A mice↗Schwann cells orchestrate peripheral nerve inflammation through the expression of CSF1, IL-34, and SCF in amyotrophic lateral sclerosis↗Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial↗Mast cells and neutrophils mediate peripheral motor pathway degeneration in ALS↗Evidence for mast cells contributing to neuromuscular pathology in an inherited model of ALS↗ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment?↗Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis↗Autoimmune-like hepatitis during masitinib therapy in an amyotrophic lateral sclerosis patient↗
Maladie d’Alzheimer — 7 publications disponibles
Masitinib attenuates neuropathological changes in acrolein-induced sAD mouse model via NF-κB/NLRP3/Caspase-1 signaling pathway↗Mast cell deficiency improves cognition and enhances disease-associated microglia in 5XFAD mice↗Mast cell and astrocyte hemichannels and their role in Alzheimer’s disease, ALS, and harmful stress conditions↗Masitinib in mild to moderate Alzheimer’s disease: results from study AB09004↗Effects of chronic masitinib treatment in APPswe/PSEN1dE9 transgenic mice modeling Alzheimer’s disease↗Masitinib for the treatment of mild to moderate Alzheimer’s disease↗Masitinib as an adjunct therapy for mild-to-moderate Alzheimer’s disease: a randomised, placebo-controlled phase 2 trial↗
AB8939 — 5 publications disponibles
Identification of AB8939, a novel synthetic microtubule destabilizer and ALDH inhibitor that overcomes multidrug resistance in tumor cells as a drug candidate for the treatment of refractory acute myeloid leukemia↗AB8939, a novel microtubule-destabilizing agent for the treatment of acute myeloid leukemia (abstract EP465)↗In vivo assessment of the next generation microtubule-destabilizing agent AB8939 in patient-derived xenograft models of acute myeloid leukemia↗Anticancer activity of a highly potent small molecule tubulin polymerization inhibitor, AB8939↗AB8939, a microtubule-destabilizing agent with potential to overcome multidrug resistance, is active across the range (M0-M7) of acute myeloid leukemia subtypes↗